Royal Bank Of Canada Acurx Pharmaceuticals, Inc. Transaction History

Royal Bank Of Canada

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.64 - $2.79 $155 - $265	95 Added 256.76%	132 $0
Q1 2024 Nov 05, 2024	SELL	$1.94 - $4.81 $184 - $456	-95 Reduced 71.97%	37 $0
Q1 2024 May 15, 2024	SELL	$1.94 - $4.81 $31 - $76	-16 Reduced 30.19%	37 $0
Q4 2023 Feb 14, 2024	BUY	$1.28 - $5.76 $28 - $126	22 Added 70.97%	53 $0
Q3 2023 Nov 14, 2023	SELL	$1.41 - $2.55 $126 - $229	-90 Reduced 74.38%	31 $0
Q2 2023 Aug 14, 2023	BUY	$2.47 - $3.53 $298 - $427	121 New	121 $0
Q3 2022 Nov 14, 2022	BUY	$3.0 - $4.78 $261 - $415	87 New	87 $0

1.25M

9.3K

9.7K

Ticker ACXP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,556,600
Market Cap $19.3M
Description
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.